How should I administer the Capizzi interim‑maintenance regimen (3‑week cycles, 6–8 cycles) for a child or adolescent with acute lymphoblastic leukemia in remission?

How to Administer the Capizzi Protocol for Pediatric ALL

The Capizzi interim-maintenance regimen consists of escalating-dose intravenous methotrexate starting at 100 mg/m² and increasing by 50–100 mg/m² weekly to a maximum of 1000 mg/m² over 8 weeks, with each dose given as a 30-minute loading dose followed by the remaining 90% over 23.5 hours, followed 24 hours later by intramuscular PEG-asparaginase 2500 U/m², without leucovorin rescue. 1

Cycle Structure and Timing

• The Capizzi regimen is administered during the 8-week interim-maintenance phase that follows consolidation therapy in pediatric ALL treatment protocols 1
• This phase is typically repeated for 6–8 cycles as part of the overall treatment backbone 2
• The regimen has demonstrated superior outcomes compared to high-dose methotrexate (5 g/m²) specifically in T-cell ALL patients ≤30 years, with 5-year disease-free survival of 91.5% versus 85.3% (P=0.005) 2

Methotrexate Administration Protocol

Dosing Schedule

• Week 1: Start at 100 mg/m² IV 1
• Weeks 2–8: Escalate by 50–100 mg/m² each week 1
• Maximum dose: 1000 mg/m² (do not exceed) 1

Infusion Technique

• Administer 10% of the total dose as a 30-minute loading infusion 1
• Deliver the remaining 90% as a continuous infusion over 23.5 hours 1
• Critical: No leucovorin rescue is given with Capizzi methotrexate, which distinguishes it from high-dose methotrexate protocols 1

PEG-Asparaginase Integration

• Give PEG-asparaginase 2500 U/m² intramuscularly exactly 24 hours after completion of each methotrexate infusion 1
• The asparaginase depletes asparagine, which synergizes with methotrexate by prolonging its intracellular retention 1

Mandatory Supportive Care Measures

Hydration Protocol

• Begin aggressive IV hydration at 125–150 mL/m²/hour starting 12 hours before methotrexate infusion 1
• Continue hydration for 24–36 hours after infusion completion 1
• Maintain urine output >100 mL/m²/hour throughout 1

Urine Alkalinization

• Add sodium bicarbonate to IV fluids to maintain urine pH >7.0 1
• This prevents methotrexate precipitation in renal tubules and reduces nephrotoxicity 1
• Check urine pH every 6 hours during and after infusion 1

Monitoring Requirements

Renal Function Surveillance

• Measure serum creatinine at baseline, 24 hours, and 48 hours after each methotrexate infusion 1
• If creatinine rises >50% from baseline, hold subsequent doses and consider leucovorin rescue despite protocol design 3

Toxicity Monitoring

• Asparaginase-related: Monitor for coagulopathy, thrombosis, hyperglycemia, pancreatitis, and hepatotoxicity after each dose 1
• Methotrexate-related: Watch for mucositis, pancytopenia, hepatotoxicity, and dermatologic toxicities 3
• Obtain CBC with differential before each weekly dose 3
• Check liver function tests (AST, ALT, bilirubin) weekly 1

CNS Prophylaxis Integration

• Because Capizzi methotrexate achieves relatively low CSF concentrations compared to high-dose protocols, concurrent intrathecal methotrexate must be administered 1
• Give intrathecal methotrexate on weeks 1 and 3 of each 8-week cycle 1
• Age-based intrathecal dosing: <1 year = 6 mg; 1–2 years = 8 mg; 2–3 years = 10 mg; ≥3 years = 12 mg 2

Dose Modifications and Contraindications

Renal Impairment

• For creatinine clearance <60 mL/min, reduce initial methotrexate dose by 50% 1
• Escalate subsequent doses more cautiously (25 mg/m² increments instead of 50–100 mg/m²) 1

Hepatic Dysfunction

• If transaminases >5× upper limit of normal, reduce methotrexate dose by 50% or consider alternative regimen 1
• Do not administer if bilirubin >3 mg/dL 1

Active Infection

• Postpone the cycle until infection is resolved and patient is afebrile for 48 hours 1
• Do not reduce doses to accommodate infection; delay is preferred 1

Absolute Contraindications

• Pregnancy (effective contraception mandatory throughout treatment) 1
• Severe pleural effusion or ascites (methotrexate accumulates in third-space fluid) 1

Critical Safety Considerations

Leucovorin Rescue Caveat

• The absence of leucovorin rescue in Capizzi protocol puts patients at higher risk for severe multiorgan toxicity 3
• If severe toxicity develops (grade 3–4 mucositis, pancytopenia, or dermatologic toxicity), immediately administer high-dose leucovorin 100 mg/m² IV every 6 hours until toxicity resolves 3
• One case report documented severe multiorgan toxicity after a single intermediate dose, requiring aggressive leucovorin rescue 3

Neurotoxicity Risk

• Patients who previously received cranial irradiation and intensive intrathecal therapy are at increased risk for neurotoxicity with Capizzi methotrexate 4
• Monitor for confusion, seizures, or focal neurologic deficits 4

Timing of Oral Medications

• If maintenance oral mercaptopurine or methotrexate is given concurrently, administer in the evening (before bedtime) rather than morning 5
• Evening administration reduces relapse risk by 4.6-fold compared to morning dosing 5

Treatment Setting Requirements

• Capizzi protocol should only be administered in centers with 24-hour access to intensive care, nephrology consultation, and emergency leucovorin availability 3
• Pharmacy must be capable of preparing extended-infusion methotrexate with precise dosing 1